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TO THE EDITOR
The studies described in our paper 1 focused on the comparison of two methods of quantitative PCR that are used to estimate levels of BCR-ABL transcripts in minimal residual disease patients with chronic myelogenous leukemia (CML). This investigation was prompted by our observation that levels of BCR-ABL transcripts were routinely underestimated by the realtime PCR method compared to the competitive PCR method. In addition, we observed that the competitive PCR method was more sensitive than the real-time method.
The correspondence by Rawer et al 2 raised important issues. First, they agreed with our findings concerning the increased sensitivity of the competitive method compared to real-time method, stating that 'the greater number of PCR cycles in a nested competitive PCR assay may provide improved sensitivity of this approach when compared to real-time like Taqman (usually 65-75 vs 40 cycles)'. Secondly, they raised doubts about our finding with one of the samples, which showed 0.1 transcripts per microgram of total RNA. Unfortunately, we found that an error was made in setting the galley proof on this data point (no others errors were detected). The original data in our manuscript listed this value as 10 transcripts per microgram of total RNA and not 0.1 transcripts (100-fold difference). This is an unfortunate error, which we failed to uncover in the galley proof. Thus, the arguments put forward by Rawer et al on this result are rendered less important by this error. Using the calculations of Rawer et al, we estimate that the assay tube would contain 3.125 transcripts of BCR-ABL and not 0.03125 transcripts.
The third point requires serious discussion. It concerned samples that scored negative in our assays. Rawer et al are correct in suggesting that the Poisson distribution concept is operative. The number of measurement repetitions is relevant in the detection of rare transcripts. Table 1 shows the probability of observing at least one positive score with number of repetitions from 1 to 8 under the Poisson assumption. For example, with three replicates (which is the number of RT-PCR assays conducted for the Guo et al 1 study), there is a 95% chance to detect at least one positive score when the expected value is 1. Eight replicates would pick up the remaining 5%, but it is not clear that this improvement in sensitivity is worth the cost.
As a practical matter, it is unrealistic to perform sufficient replicate assays to determine whether a given sample is in fact negative or positive with a relatively low value. It is too costly and too time consuming for a clinical lab operation in which many samples must be assayed. Moreover, as discussed in the Discussion section of our paper, 1 the value of a single quantitative PCR data point is less important than the trend of values over a period of time. In our experience, some CML patients have detectable transcripts at very low levels, but their transcript numbers do not increase significantly during long periods of follow-up. Investigators in the field consider the trend of the quantitative PCR results is one of the critical issues. 3 This 'trend' point of view stems from the fact that: (1) PCR assays have an intrinsic variability and thus determining the precise transcript number will require replicate assays (Poisson distribution considerations) and (2) more importantly, any single assay result depends on several factors. These include the variability of RNA degradation in a given sample preparation, the efficiency In Poisson distribution, the variance of numbers ought to equal the mean of numbers. The index of dispersion, R(t), as the ratio of the variance to the mean, should be close to 1. The approximation of R(t) to 1 may serve as a marker to demonstrate the existence of the Poisson distribution of the replicates on each distinct copy step.
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of extraction, and the degree of antileukemia responses due to therapy, and the antileukemia immune responses that may be occurring in the patient (see below). Just as important are the clinical issues, 4 that is, it is premature to draw firm conclusions about whether a patient requires reinstatement of therapy or discontinuance of therapy based solely on quantitative RT-PCR results.
The idealized experiment listed in the table shown in Rawer et al 2 reflects the fact that Poisson distribution is a truism. However, patient samples have day-to-day variances that affect the levels of transcripts/assay tube that are often uncontrollable (as described above).
Another issue relates to the sensitivity of these quantitative PCR assays. Nested PCR for BCR-ABL RNA can detect a single leukemia cell in a background of 10e5 to 10e6 normal cells. A volume of 10-40 ml of blood (or several ml of marrow) represents only a very small fraction of the total blood volume. Patients in clinical remission might have a preponderance of blood cells that lack BCR-ABL transcripts. Thus, a negative result for BCR-ABL transcripts could mean either that value is below the limit of detection given the limitation of the sampling (eg less than 40 ml blood) or the assay limitation itself. A patient with a negative value might still have a significant population of BcrAbl positive blood cells either in circulation, in the marrow or in various tissues (eg spleen). Assay limitations may be reduced as the technology improves. However, sampling limitations will be difficult to overcome.
Lastly, the role of immune surveillance in the control of CML is not well understood. Many believe that immune-based antileukemia effects are significant, especially in patients with minimal residual disease. 4 Importantly, these immune surveil- We thank Arlinghaus and his co-workers for their detailed reply and the additional information. 1 However, to clarify the point, we do not share the common belief that 75 cycles are more sensitive than 40 or 45. This assumption may be correct for end point techniques but not for real-time PCR.
If only a single template is present in a real-time PCR, the reaction will become undoubtedly visible after a given number of cycles as an amplification plot. If there is no template, it will not. Unlike in end point techniques that are based on simple fluorescent signals, there is nothing in between 1 and 0 copies, as it is possible to distinguish an amplification plot and a nonamplification plot by regarding its slope. 2 The exact cycle number needed depends on the PCR efficiency that can easily be determined in real-time PCR. Typically it varies around 40.
In their original paper, the group of Arlinghaus stated 'that nested, competitive RT-PCR [should] be used to determine BCR-ABL/ABL transcript ratios at low level transcript values or especially when real-time analysis are negative'. 3 This conclusion was based on samples that were scored negative in real-time PCR but positive in competitive PCR. They did not, however, present data to clarify whether real-time PCR was false-negative or nested PCR was false-positive.
To address this question experimentally, we reasoned that if sensitivity of real-time PCR was near 100%, we would be able to 
